CYP2C19*2 and CYP2C19*17 polymorphisms in the treatment of schizophrenia

CYP2C19*2 and CYP2C19*17 polymorphisms in the treatment of schizophrenia

Evaluation of the influence of CYP2C19*2 and CYP2C19*17 polymorphisms on the response to clozapine treatment in schizophrenia

Versandkostenfrei!
Versandfertig in 1-2 Wochen
18,99 €
inkl. MwSt.
PAYBACK Punkte
9 °P sammeln!
The treatment of schizophrenia, as a severe mental illness manifested through hallucinations and persistent delusions, with negative impacts on the personal, family and socio-economic lives of patients, has required from the scientific field important genetic and pharmacological interventions and research, since the effectiveness and efficiency of certain drugs is also associated with individual genetic variability.Studies have shown that more than 30% of schizophrenic patients do not respond effectively to clozapine, thus constituting the group of over-refrenquished patients. Given that CYP2C...